Acc2014 13
14
Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
-
Upload
astrazenecaoz -
Category
Health & Medicine
-
view
32 -
download
0
description
Acc2014 13
Transcript of Acc2014 13
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Clinical effects of introducing high sensitivity troponin T testing: SWEDEHEART registry data
Commentary:Professor David Brieger
Concord Hospital, Sydney
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Baseline characteristics
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
In-hospital course
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
In-hospital course
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
1-year mortality
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Adjusted all-cause mortality by hs-cTnT
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Data from this very large Swedish registry confirms that the introduction of high-sensitivity troponin assays substantially expands the pool of patients with ‘elevated’ troponin T levels.
• Importantly, the analysis confirms the prognostic significance of troponin T, showing a clear association with all-cause mortality once the level exceeds 14 ng/mL.
Commentary: Professor David Brieger
